MTOR and neoplasm: For example, Sunitinib, a tyrosine kinase inhibitor (TKI), impedes tumor angiogenesis and expansion through Vascular Endothelial Growth Factor Receptor(VEGFR) disruption (9), while Everolimus and Temsirolimus, mammalian target of rapamycin (mTOR) inhibitors, hinder tumor growth and proliferation by modulating the mTOR signaling cascade (10–12).